ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,459.10
      1.11%
      US Tech 100
      18,514.00
      1.00%
      Dow Jones
      40,589.34
      1.64%
      Brent Oil
      79.745
      0.00%
      Bitcoin
      69,004.91
      1.61%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. Acticor Biotech (ALACT) Quote

      Acticor Biotech

      Acticor Biotech (ALACT)

      EU
      0.48
      -0.06
      (-11.11%)
      Closed July 27 11:30AM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      0.48
      Bid
      0.48
      Ask
      0.50
      Volume
      21,841
      0.48 Day's Range 0.51
      0.27 52 Week Range 6.00
      Market Cap
      7.563M
      Previous Close
      0.54
      Open
      0.51
      Last Trade
      250
      @
      0.48
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      75,368
      Shares Outstanding
      15,755,227
      Dividend Yield
      -
      PE Ratio
      -0.48
      Earnings Per Share (EPS)
      -1.01
      Revenue
      2.7M
      Net Profit
      -15.88M

      About Acticor Biotech

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.acticor-biotech.com
      Headquarters
      Paris, Paris, Fra
      Founded
      1970
      Acticor Biotech is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALACT. The last closing price for Acticor Biotech was 0.54 €. Over the last year, Acticor Biotech shares have traded in a share price range of 0.27 € to 6.00 €.

      Acticor Biotech currently has 15,755,227 shares outstanding. The market capitalization of Acticor Biotech is 8.51 € million. Acticor Biotech has a price to earnings ratio (PE ratio) of -0.48.

      ALACT Latest News

      More News

      Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the GREEN Study

      Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...

      July 26 2024
      Business Wire

      ACTICOR BIOTECH : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE KEPLER CHEUVREUX

      Regulatory News:  ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), société biopharmaceutique au stade clinique qui développe le glenzocimab, un médicament innovant pour le traitement des urgences...

      July 18 2024
      Business Wire

      Acticor Biotech : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 juin 2024

      Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), société biopharmaceutique au stade clinique qui développe...

      July 17 2024
      Business Wire

      Acticor Biotech publishes its 2023 annual results

      Annual General Meeting to be held on September 13, 2024, to approve the financial statements for the year ending December 31, 2023 Update on the glenzocimab clinical development plan published...

      July 09 2024
      Business Wire

      Acticor Biotech: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2024

      Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), société biopharmaceutique au stade clinique qui développe...

      July 05 2024
      Business Wire

      Acticor Biotech fait le point sur le plan de développement clinique du glenzocimab dans le traitement des urgences cardio-vasculaires

      Nouvelles analyses de l’étude de phase 2/3 ACTISAVE démontrant des tendances favorables pour le glenzocimab sur des sous-populations de patients Poursuite des études cliniques : GREEN de phase...

      June 03 2024
      Business Wire

      Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

       Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies     New analyses of ACTISAVE phase 2/3 study show positive trends for...

      June 03 2024
      GlobeNewswire Inc.

      Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024

      Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...

      May 27 2024
      Business Wire

      The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

      University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first...

      February 07 2024
      GlobeNewswire Inc.

      Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

      Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke    438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in...

      November 07 2023
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.102-17.52577319590.5820.5820.4834510.54816609DE
      4-0.23-32.39436619720.710.710.421124540.5387968DE
      120.09123.39331619540.3891.240.38753680.86355955DE
      26-3.92-89.09090909094.45.30.27707161.0602823DE
      52-5.06-91.33574007225.5460.27380911.27650964DE
      156-6.62-93.23943661977.1110.27159482.01397905DE
      2600.307177.4566473990.173110.11669041.19674533DE

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WINTWindtree Therapeutics Inc
      $ 8.24
      (150.46%)
      		48.57M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NBSTWNewbury Street Acquisition Corporation
      $ 0.1349
      (92.71%)
      		122.1k
      YIBOPlanet Image International Ltd
      $ 2.915
      (53.43%)
      		260.07k
      CREVCarbon Revolution Public Ltd
      $ 9.00
      (45.87%)
      		8.06M
      NMHINatures Miracle Holding Inc
      $ 0.2035
      (-48.06%)
      		7.69M
      TANHTantech Holdings Ltd
      $ 0.2585
      (-47.23%)
      		6.75M
      DXCMDexCom Inc
      $ 64.00
      (-40.66%)
      		53.92M
      PSIGPS International Group Ltd
      $ 1.42
      (-31.40%)
      		716.26k
      POAIPredictive Oncology Inc
      $ 1.36
      (-27.27%)
      		6.02M
      SLNASelina Hospitality PLC
      $ 0.0305
      (-18.88%)
      		408.61M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NVDANVIDIA Corporation
      $ 113.06
      (0.69%)
      		293.33M
      SQQQProShares UltraPro Short QQQ
      $ 9.10
      (-2.88%)
      		176.49M
      SGMOSangamo Therapeutics Inc
      $ 0.8612
      (28.15%)
      		123.71M

      Discussion

      View Full Feed
      jeunke22 jeunke22 2 minutes ago
      Remember the times many here were bitching on Dan Kehler? How could Niocorp sell out that cheap? NB shares for our new director: SPAC didn’t work out. Kehler put his money into Niocorp.
      None of our board members, that includes Kehler, have sold any shares.
      I remember my discussions
      NB
      Fire_starter Fire_starter 2 minutes ago
      WORLD-WIDE BREAKOUT🔥🔥🔥🔥🔥

      TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

      BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASD
      RNAZ
      learningcurve2020 learningcurve2020 2 minutes ago
      You can almost hear the "Thundering herds"!
      NWBO
      back2basics back2basics 2 minutes ago
      Those two big oceans separating us from Asia and Europe no longer act as the moat around our castle. They are too easily breached."

      Well put, K-Lady. And they haven't for a long time. In'42 & '43 there were over 400 consecutive days when torpedoed ships could be seen burning off the
      hssbwwmp hssbwwmp 2 minutes ago
      More on the many Aegis investor losses including SBFM:

      https://www.linkedin.com/pulse/aegis-capital-farm-to-table-securities-fraud-purveyor-craig-mccann-gjose
      SBFM
      Biowatch Biowatch 2 minutes ago
      posting YouTube videos tends to be a challenge in general. You have to use [YT] (insert YouTube code here but make sure you delete the space before the identification code in order to make it work, then add) [/yt]
      delerious1 delerious1 3 minutes ago
      I always wonder why the so called truth telling Bashers are so angry at regular shareholders and stock traders
      capgain capgain 4 minutes ago
      Pretty good stuff :)
      Welcome2Pinkyland Welcome2Pinkyland 4 minutes ago
      I did experience the website locking up on me yesterday.
      learningcurve2020 learningcurve2020 4 minutes ago
      They deleted my post:

      Bio---- is absurd. Also, unless I missed it, nowhere in the filings does it say LP has ownership by way of Toucan in the UK CDMO, and during the ASM Les went out of his way not to mention it only saying they have a special relationship, or whatever it was he said
      ASM CDMO
      tat4tat tat4tat 5 minutes ago
      Disappointing response to Verizon news especially on a day when Dow was up over 800. Expected much more. Earnings next month shoud help.
      SYTA
      ANTI-BAGHOLDER ANTI-BAGHOLDER 5 minutes ago
      It’s pure ignorance really
      Biowatch Biowatch 5 minutes ago
      Not sure what this is about…
      mmayr mmayr 6 minutes ago
      I often have a difficult time posting videos on my thread: https://investorshub.advfn.com/All-Star-Economic-News-2434. Sometimes IHub locks up. This has happened to me on a couple of different computer systems. I'm not sure if it is because I have multiple windows open or if it is a concern with
      Sims1212 Sims1212 6 minutes ago
      Be careful don't laugh too hard you may tinkle in your Depends pillow biter.Now go plug the holes in your canoe lmfao
      SHIBUSD
      Susie924 Susie924 6 minutes ago
      That’s amazing.
      janice shell janice shell 6 minutes ago
      Your point, whatever it is, might be clearer if you'd explain you removed original content that DID violate the TOU.
      capgain capgain 7 minutes ago
      Love it!
      sage4 sage4 7 minutes ago
      You both are sick!
      AVXL
      janice shell janice shell 8 minutes ago
      Ohhhh.... I see. That makes sense.
      Chartmaster Chartmaster 8 minutes ago
      Thinkin 18-23 next week could be buyin OP
      HIRU
      hssbwwmp hssbwwmp 8 minutes ago
      A current investigation of Aegis and SBFM:
      https://klaymantoskes.com/investigations/sunshine-biopharma-inc-aegis-capital-investor-loss-investigation/
      SBFM
      DewDiligence DewDiligence 8 minutes ago
      During the time it is in the body, the drug can do its job… Some drugs continue to do their job long after they have been excreted; botulinum toxins are one such example—see #msg-174821940.
      capgain capgain 9 minutes ago
      Love to hear that news Gmen.

      Your Recent History

      EU
      ALACT
      Acticor Biotech
      Delayed Upgrade Clock